David Herzberg – författare

The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs, David Herzberg explores these crises and the drugs that fueled them, from Bayer's Heroin to Purdue's OxyContin and all the drugs in between: barbiturate "goof balls," amphetamine "thrill pills," the "love drug" Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls "white markets," where the prescription of addictive drugs is legal and medically approved. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its "drug wars"--until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America's divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets while caring for people with addiction by ensuring them safe, reliable access to medication-assisted treatment. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself--ideas that have been failing us catastrophically for over a century.

The first critical analysis of how Whiteness drove the opioid crisis.  In the past two decades, media images of the surprisingly white “new face” of the US opioid crisis abounded. But why was the crisis so white? Some argued that skyrocketing overdoses were “deaths of despair” signaling deeper socioeconomic anguish in white communities. Whiteout makes the counterintuitive case that the opioid crisis was the product of white racial privilege as well as despair.  Anchored by interviews, data, and riveting firsthand narratives from three leading experts—an addiction psychiatrist, a policy advocate, and a drug historian—Whiteout reveals how a century of structural racism in drug policy, and in profit-oriented medical industries led to mass white overdose deaths. The authors implicate racially segregated health care systems, the racial assumptions of addiction scientists, and relaxed regulation of pharmaceutical marketing to white consumers. Whiteout is an unflinching account of how racial capitalism is toxic for all Americans.

The first critical analysis of how Whiteness drove the opioid crisis.   In the past two decades, media images of the surprisingly white “new face” of the US opioid crisis abounded. But why was the crisis so white? Some argued that skyrocketing overdoses were “deaths of despair” signaling deeper socioeconomic anguish in white communities. Whiteout makes the counterintuitive case that the opioid crisis was the product of white racial privilege as well as despair.   Anchored by interviews, data, and riveting firsthand narratives from three leading experts—an addiction psychiatrist, a policy advocate, and a drug historian—Whiteout reveals how a century of structural racism in drug policy, and in profit-oriented medical industries led to mass white overdose deaths. The authors implicate racially segregated health care systems, the racial assumptions of addiction scientists, and relaxed regulation of pharmaceutical marketing to white consumers. Whiteout is an unflinching account of how racial capitalism is toxic for all Americans.

The first critical analysis of how Whiteness drove the opioid crisis.  In the past two decades, media images of the surprisingly white “new face” of the US opioid crisis abounded. But why was the crisis so white? Some argued that skyrocketing overdoses were “deaths of despair” signaling deeper socioeconomic anguish in white communities. Whiteout makes the counterintuitive case that the opioid crisis was the product of white racial privilege as well as despair.  Anchored by interviews, data, and riveting firsthand narratives from three leading experts—an addiction psychiatrist, a policy advocate, and a drug historian—Whiteout reveals how a century of structural racism in drug policy, and in profit-oriented medical industries led to mass white overdose deaths. The authors implicate racially segregated health care systems, the racial assumptions of addiction scientists, and relaxed regulation of pharmaceutical marketing to white consumers. Whiteout is an unflinching account of how racial capitalism is toxic for all Americans.

Valium. Paxil. Prozac. Prescribed by the millions each year, these medications have been hailed as wonder drugs and vilified as numbing and addictive crutches. Where did this "blockbuster drug" phenomenon come from? What factors led to the mass acceptance of tranquilizers and antidepressants? And how has their widespread use affected American culture? David Herzberg addresses these questions by tracing the rise of psychiatric medicines, from Miltown in the 1950s to Valium in the 1970s to Prozac in the 1990s. The result is more than a story of doctors and patients. From bare-knuckled marketing campaigns to political activism by feminists and antidrug warriors, the fate of psychopharmacology has been intimately wrapped up in the broader currents of modern American history. Beginning with the emergence of a medical marketplace for psychoactive drugs in the postwar consumer culture, Herzberg traces how "happy pills" became embroiled in Cold War gender battles and the explosive politics of the "war against drugs"-and how feminists brought the two issues together in a dramatic campaign against Valium addiction in the 1970s.A final look at antidepressants shows that even the Prozac phenomenon owed as much to commerce and culture as to scientific wizardry. With a barrage of "ask your doctor about" advertisements competing for attention with shocking news of drug company malfeasance, Happy Pills is an invaluable look at how the commercialization of medicine has transformed American culture since the end of World War II.